Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by (1,018)

Items 1,001–1,018 of 1,018

1. A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors
   Shaikh, Fyza Y., White, James R., Gills, Joell J., Hakozaki, Taiki, Richard, Corentin, Routy, Bertrand, Okuma, Yusuke, Usyk, Mykhaylo, Pandey, Abhishek, Weber, Jeffrey S. et al. · 2021 · Clinical Cancer Research
2. More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
   Lietman, Caressa D., Johnson, Melissa L., McCormick, Frank, Lindsay, Colin R. · 2022 · American Society of Clinical Oncology Educational Book
3. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
   Felip, E., Rojas, C.I., Schenker, M., Kowalski, D.M., Casarini, I.A., Csöszi, T., Şendur, M.A.N., Martins, J., Calles Blanco, A., Wang, C.-C. et al. · 2025 · Annals of Oncology
4. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects
   Petrazzuolo, Adriana, Perez-Lanzon, Maria, Martins, Isabelle, Liu, Peng, Kepp, Oliver, Minard-Colin, Véronique, Maiuri, Maria Chiara, Kroemer, Guido · 2021 · Cell Death & Disease
5. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
   Qiu, Hui, Shao, Zhiying, Wen, Xin, Jiang, Jinghua, Ma, Qinggong, Wang, Yan, Huang, Long, Ding, Xin, Zhang, Longzhen · 2021 · Frontiers in Immunology
6. Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology
   Jamal, Rahima, Messaoudene, Meriem, de Figuieredo, Marina, Routy, Bertrand · 2023 · Seminars in Immunology
7. Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis
   Miao, Jing, Herrmann, Sandra M · 2023 · Clinical Kidney Journal
8. Pembrolizumab for advanced cervical cancer: Safety and efficacy
   De Felice, Francesca, Giudice, Elena, Bolomini, Giulia, Distefano, Maria Grazia, Scambia, Giovanni, Fagotti, Anna, Marchetti, Claudia · 2021 · Expert Review of Anticancer Therapy
9. Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors
   Shaikh, Fyza Y., Gills, Joell J., Mohammad, Fuad, White, James R., Stevens, Courtney M., Ding, Hua, Fu, Juan, Tam, Ada, Blosser, Richard L., Domingue, Jada C. et al. · 2022 · Cancer Immunology, Immunotherapy
10. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Zhao, Dan, Li, Haiqing, Mambetsariev, Isa, Mirzapoiazova, Tamara, Chen, Chen, Fricke, Jeremy, Kulkarni, Prakash, Villaflor, Victoria, Arvanitis, Leonidas, Hamilton, Stanley et al. · 2022 · Cancers
11. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer
    Koyama, Junji, Horiike, Atsushi, Yoshizawa, Takahiro, Dotsu, Yosuke, Ariyasu, Ryo, Saiki, Masafumi, Sonoda, Tomoaki, Uchibori, Ken, Nishikawa, Shingo, Kitazono, Satoru et al. · 2019 · Journal of Thoracic Disease
12. Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors
    Mahiat, Cédric, Bihin, Benoît, Duplaquet, Fabrice, Stanciu Pop, Claudia, Dupont, Michael, Vander Borght, Thierry, Rondelet, Benoît, Vanderick, Jean, André, Bénédicte, Pirard, Lionel et al. · 2023 · International Journal of Molecular Sciences
13. The Next Generation of KRAS Targeting: Reasons for Excitement and Concern
    Akhave, Neal S., Biter, Amadeo B., Hong, David S. · 2022 · Molecular Cancer Therapeutics
14. Clinical impact of inflammatory and nutrition index based on metabolic tumor activity in non‑small cell lung cancer treated with immunotherapy.
    Ito, Koki, Hashimoto, Kousuke, Kaira, Kyoichi, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Kobayashi, Kunihiko, Imai, Hisao, Kuji, Ichiei et al. · 2024 · Oncology Letters
15. Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium
    Barber, Emma L., Chen, Siqi, Pineda, Mario Javier, Robertson, Sharon E., Hill, Emily K., Teoh, Deanna, Schilder, Jeanne, O'Shea, Kaitlyn L., Kocherginsky, Masha, Zhang, Bin et al. · 2022 · Cancer Research Communications
16. Genetic variants as predictors of toxicity and response in patients with non‐small cell lung cancer undergoing first‐line platinum‐based chemotherapy: Design of the multicenter PGxLUNG study
    de Jong, Corine, Herder, Gerarda J.M., Deneer, Vera H.M. · 2020 · Thoracic Cancer
17. Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
    Shi, Yuankai, Bi, Minghong, Li, Qingshan, Wang, Guolei, Chen, Jianhua, Li, Mingjun, Shi, Jianhua, Mei, Jiazhuan, Ji, Yinghua, Xia, Qingdi et al. · 2025 · Cancer Pathogenesis and Therapy
18. Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study
    Oduah, Eziafa I., Zhang, Tian, Jung, Sin-Ho, Stinchcombe, Thomas E., Ready, Neal, Crawford, Jeffrey, Clarke, Jeffrey M., Gray, Jhanelle E., Antonia, Scott J. · 2026 · Future Oncology